TRV 250
Alternative Names: TRV-250Latest Information Update: 28 Apr 2025
At a glance
- Originator Trevena
- Class Analgesics; Antimigraines; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Migraine
- No development reported CNS disorders
- Discontinued Neuropathic pain; Parkinson's disease
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Migraine(In volunteers) in USA (PO)
- 10 Apr 2023 Trevena has one pending provisional patent application for synthesis of TRV250 and methods of using it